EQS-News: Zur Rose Group successfully concluded acquisition of TeleClinic

Primary tabs

The Zur Rose Group has successfully completed the acquisition of TeleClinic GmbH, Munich.

Information
Retrieved on: 
Friday, July 31, 2020 - 6:01pm
Stock Symbol: 
Geotags: 
Content
Key Points: 
  • The Zur Rose Group has successfully completed the acquisition of TeleClinic GmbH, Munich.
  • For the Zur Rose Group, the acquisition is a strategically important building block, adding complementary telemedicine services to the Zur Rose Healthcare Ecosystem.
  • The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland.
  • The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE).



EQS Group-News: Zur Rose Group AG

/ Key word(s): Takeover


Zur Rose Group successfully concluded acquisition of TeleClinic

31.07.2020 / 18:30


Press release

Zur Rose Group successfully concluded acquisition of TeleClinic


The Zur Rose Group has successfully completed the acquisition of TeleClinic GmbH, Munich. TeleClinic has rapidly achieved the status of the leading telemedicine provider in Germany. For the Zur Rose Group, the acquisition is a strategically important building block, adding complementary telemedicine services to the Zur Rose Healthcare Ecosystem.

Investors and analyst contact

Christoph Herrmann, Head of Investor Relations

Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact

Lisa Lüthi, Head of Group Communications

Email: media@zurrose.com, phone: +41 52 724 08 14

Agenda

19 August 2020 Half-Year Results

21 October 2020 Q3 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around nine million active customers in core European markets.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.




End of Corporate News


Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Switzerland
Phone: +41 52 724 08 14
Internet: www.zurrosegroup.com
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1105171



 
End of News EQS Group News Service

1105171  31.07.2020 

fncls.ssp?fn=show_t_gif&application_id=1105171&application_name=news&site_id=jotup